Publications by authors named "Susan Raber"

Claim this Profile
C
Comparative Analysis of Isavuconazole DDIs With Other Azole Antifungal Drugs and PBPK Model-Informed Dosing Recommendations for Anticancer Drugs.
Theunis C Goosen, Xiaofeng Wu, Jian Lin, Narayan Cheruvu, Susan R Raber

CPT Pharmacometrics Syst Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microbiological, Clinical, and Pharmacokinetic/Pharmacodynamic Data to Support EUCAST Aztreonam-Avibactam Minimum Inhibitory Concentration Susceptibility Breakpoints Against Enterobacterales.
Susan R Raber, Rujia Xie, Halley Rogers, Elena Soto, Francis F Arhin

Infect Dis Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients.
Rujia Xie, Halley Rogers, Joseph W Chow, Elena Soto, Susan R Raber

Antimicrob Agents Chemother· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of Intramuscular Injectable Benzathine Penicillin G in Japanese Healthy Participants.
Yinhua Li, Akifumi Okayama, Toshiaki Hagi, Chieko Muto, Susan Raber

J Clin Pharmacol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation.
Shampa Das, Todd Riccobene, Timothy J Carrothers, James G Wright, Merran MacPherson, Susan Raber

Eur J Clin Pharmacol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older.
Richard C Franzese, Lynn McFadyen, Kenny J Watson, Todd Riccobene, Timothy J Carrothers, Susan Raber

Clin Pharmacol Ther· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of extrapolation based on modeling and simulation to support high-dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft-tissue infections.
Phylinda L S Chan, Lynn McFadyen, Andrea Quaye, Heidi Leister-Tebbe, Victoria M Hendrick, Susan Raber

CPT Pharmacometrics Syst Pharmacol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5-Minute Infusion.
Todd A Riccobene, Timothy J Carrothers, William Knebel, Susan Raber, Phylinda L S Chan

Clin Pharmacol Drug Dev· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Analysis of Anidulafungin in Infants to Older Adults With Confirmed or Suspected Invasive Candidiasis.
Rujia Xie, Lynn McFadyen, Susan Raber, Robert Swanson, Margaret Tawadrous

Clin Pharmacol Ther· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Ceftaroline Fosamil in Neonates and Very Young Infants With Late-onset Sepsis.
John S Bradley, Gregory G Stone, Phylinda L S Chan, Susan R Raber, Todd Riccobene

Pediatr Infect Dis J· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia.
Emmanuel Roilides, Fabianne Carlesse, Margaret Tawadrous, Heidi Leister-Tebbe, Umberto Conte, Susan Raber

Pediatr Infect Dis J· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study.
Oliver A Cornely, José M Cisneros, Julian Torre-Cisneros, María Jesús Rodríguez-Hernández, Luis Tallón-Aguilar, Susan Raber

J Antimicrob Chemother· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Tigecycline to Treat Multidrug-resistant Infections in Pediatrics: An Evidence Synthesis.
Mike Sharland, Keith A Rodvold, Hal R Tucker, Nathalie Baillon-Plot, Margaret Tawadrous, Susan Raber

Pediatr Infect Dis J· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators.
Andrew Cristinacce, James G Wright, Gregory G Stone, Jennifer Hammond, Lynn McFadyen, Susan Raber

Infect Dis Ther· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A model-based dose-response meta-analysis of ocular hypotensive agents as a drug development tool to evaluate new therapies in glaucoma.
Susan Raber, Jaap W Mandema, Hanbin Li, Dana J Nickens

J Ocul Pharmacol Ther· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial.
Joel M Kremer, Alan J Kivitz, Jesus A Simon-Campos, Evgeny L Nasonov, Hans-Peter Tony, Susan Raber

Arthritis Res Ther· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subclinical increased anterior stromal reflectivity with topical taprenepag isopropyl.
Ronald A Schachar, Susan Raber, Kristina V Thomas, Beth Ann M Benetz, Loretta B Szczotka-Flynn

Cornea· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Latanoprost systemic exposure in pediatric and adult patients with glaucoma: a phase 1, open-label study.
Susan Raber, Rachel Courtney, Tomoko Maeda-Chubachi, Brad D Simons, Sharon F Freedman

Ophthalmology· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
Ronald A Schachar, Susan Raber, Rachel Courtney, Min Zhang

Curr Eye Res· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-efficient higher-order crossover designs in comparative bioavailability studies.
Jihao Zhou, Ying Yuan, Rebecca Reynolds, Susan Raber, Youjuan Li

Clin Pharmacokinet· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers.
Hai-Zhi Bu, William F Pool, Ellen Y Wu, Susan R Raber, Michael A Amantea

Drug Metab Dispos· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis